Xeris Biopharma (XERS) Competitors $4.92 -0.16 (-3.15%) Closing price 04:00 PM EasternExtended Trading$4.90 -0.01 (-0.30%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XERS vs. MTSR, AKRO, ALVO, CPRX, CRNX, SRRK, MRUS, MOR, PTGX, and MLTXShould you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Metsera (MTSR), Akero Therapeutics (AKRO), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Crinetics Pharmaceuticals (CRNX), Scholar Rock (SRRK), Merus (MRUS), MorphoSys (MOR), Protagonist Therapeutics (PTGX), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Xeris Biopharma vs. Metsera Akero Therapeutics Alvotech Catalyst Pharmaceuticals Crinetics Pharmaceuticals Scholar Rock Merus MorphoSys Protagonist Therapeutics MoonLake Immunotherapeutics Xeris Biopharma (NASDAQ:XERS) and Metsera (NASDAQ:MTSR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, community ranking, dividends and analyst recommendations. Do insiders & institutionals have more ownership in XERS or MTSR? 42.8% of Xeris Biopharma shares are held by institutional investors. 6.5% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts prefer XERS or MTSR? Xeris Biopharma presently has a consensus target price of $6.25, suggesting a potential upside of 27.03%. Metsera has a consensus target price of $47.00, suggesting a potential upside of 63.88%. Given Metsera's stronger consensus rating and higher possible upside, analysts clearly believe Metsera is more favorable than Xeris Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Metsera 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer XERS or MTSR? Xeris Biopharma received 144 more outperform votes than Metsera when rated by MarketBeat users. However, 100.00% of users gave Metsera an outperform vote while only 70.14% of users gave Xeris Biopharma an outperform vote. CompanyUnderperformOutperformXeris BiopharmaOutperform Votes14870.14% Underperform Votes6329.86% MetseraOutperform Votes4100.00% Underperform VotesNo Votes Is XERS or MTSR more profitable? Metsera has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%. Company Net Margins Return on Equity Return on Assets Xeris Biopharma-33.69% N/A -17.38% Metsera N/A N/A N/A Does the media prefer XERS or MTSR? In the previous week, Xeris Biopharma had 9 more articles in the media than Metsera. MarketBeat recorded 9 mentions for Xeris Biopharma and 0 mentions for Metsera. Xeris Biopharma's average media sentiment score of 1.10 beat Metsera's score of 0.67 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Overall Sentiment Xeris Biopharma Positive Metsera Positive Which has higher earnings and valuation, XERS or MTSR? Metsera has lower revenue, but higher earnings than Xeris Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXeris Biopharma$222.55M3.46-$62.26M-$0.30-16.40MetseraN/AN/AN/AN/AN/A SummaryXeris Biopharma beats Metsera on 7 of the 12 factors compared between the two stocks. Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XERS vs. The Competition Export to ExcelMetricXeris BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$769.41M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-10.938.9226.8419.71Price / Sales3.46250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book-98.406.466.794.50Net Income-$62.26M$143.98M$3.23B$248.18M7 Day Performance6.03%3.04%4.07%1.14%1 Month Performance22.39%7.44%12.52%15.20%1 Year Performance146.00%-2.46%16.83%6.56% Xeris Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XERSXeris Biopharma4.5715 of 5 stars$4.92-3.1%$6.25+27.0%+147.8%$769.41M$222.55M-10.93290MTSRMetseraN/A$28.96-1.9%$47.00+62.3%N/A$3.04BN/A0.0081Gap DownAKROAkero Therapeutics3.827 of 5 stars$38.14-1.9%$82.33+115.9%+136.2%$3.04BN/A-10.1730Insider TradeALVOAlvotech1.7714 of 5 stars$10.07-3.7%$18.00+78.7%-27.6%$3.04B$585.60M-5.444CPRXCatalyst Pharmaceuticals4.6121 of 5 stars$24.63+1.1%$32.29+31.1%+45.9%$3.00B$534.65M20.8780Positive NewsCRNXCrinetics Pharmaceuticals3.6819 of 5 stars$30.95-0.9%$73.00+135.9%-38.0%$2.90B$760,000.00-8.30210Gap UpSRRKScholar Rock4.0186 of 5 stars$30.16-1.3%$42.67+41.5%+151.9%$2.86B$33.19M-12.83140Positive NewsEarnings ReportAnalyst RevisionGap UpMRUSMerus3.2438 of 5 stars$41.36-0.5%$84.54+104.4%+0.9%$2.86B$54.73M-10.4737Earnings ReportAnalyst ForecastMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.405 of 5 stars$45.57+2.4%$65.44+43.6%+49.1%$2.82B$207.80M17.13120News CoveragePositive NewsAnalyst ForecastMLTXMoonLake Immunotherapeutics3.2957 of 5 stars$39.20+4.2%$78.71+100.8%+4.2%$2.51BN/A-30.392Positive NewsAnalyst Upgrade Related Companies and Tools Related Companies MTSR Alternatives AKRO Alternatives ALVO Alternatives CPRX Alternatives CRNX Alternatives SRRK Alternatives MRUS Alternatives MOR Alternatives PTGX Alternatives MLTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XERS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XERS Stock Free XERS Stock Alerts